Alzheimer’s drug development is gaining investor attention, with Biogen's Leqembi and Eli Lilly's Kisunla leading the market despite their limitations in reversing the disease. Novo Nordisk is exploring semaglutide's potential benefits for early Alzheimer’s patients, while Roche and UCB are assessing new treatments amid mixed trial results. The landscape is dynamic, with significant opportunities for firms that can deliver effective therapies.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.